Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16717194
Chen YM, et al. (2006) Microtubule affinity-regulating kinase 2 functions downstream of the PAR-3/PAR-6/atypical PKC complex in regulating hippocampal neuronal polarity. Proc Natl Acad Sci U S A 103, 8534-9 16717194
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T539-p - MARK2 (rat)
Modsite: RGVSSRStFHAGQLR SwissProt Entrez-Gene
Orthologous residues
MARK2 (human): T596‑p, MARK2 iso4 (human): T542‑p, MARK2 iso10 (human): T509‑p, MARK2 iso11 (human): T596‑p, MARK2 iso13 (human): T508‑p, MARK2 iso14 (human): T562‑p, MARK2 (mouse): T593‑p, MARK2 iso3 (mouse): T539‑p, MARK2 (rat): T539‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  293 (epithelial), neuron-'brain, hippocampus', PC-12 (chromaffin)
Cellular systems studied:  primary cells
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCI (rat) co-immunoprecipitation, transfection of wild-type enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bisindolylmaleimide decrease
Downstream Regulation
Effect of modification (function):  enzymatic activity, inhibited

S573-p - Tau (rat)
Modsite: NVRSKIGsTENLKHQ SwissProt Entrez-Gene
Orthologous residues
Tau (human): S579‑p, Tau iso2 (human): S204‑p, Tau iso3 (human): S168‑p, Tau iso4 (human): S233‑p, Tau iso5 (human): S262‑p, Tau iso6 (human): S204‑p, Tau iso7 (human): S233‑p, Tau iso8 (human): S262‑p, Tau (mouse): S554‑p, Tau iso3 (mouse): S251‑p, Tau iso7 (mouse): S211‑p, Tau (rat): S573‑p, Tau (cow): S269‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  293 (epithelial), neuron-'brain, hippocampus', PC-12 (chromaffin)
Cellular systems studied:  primary cells
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MARK2 (rat) siRNA inhibition of enzyme, activation of upstream enzyme, transfection of wild-type enzyme, inhibition of upstream enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PKCI (rat) decrease